Birgitte Stiksrud1, Kristina Berg Lorvik, Dag Kvale, Tom Eirik Mollnes, Per Magne Ueland, Marius Trøseid, Kjetil Taskén, Anne M Dyrhol-Riise. 1. *Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway;†Department of Infectious Diseases, Institute of Clinical Medicine, University of Oslo, Oslo, Norway;‡Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo University Hospital, University of Oslo, Oslo, Norway;§Biotechnology Centre, University of Oslo, Oslo, Norway;‖K.G. Jebsen Centre for Inflammation Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway;¶Department of Immunology, Oslo University Hospital, Oslo, Norway;#Research Laboratory, Nordland Hospital, Bodø, Norway;**Faculty of Health Sciences, K.G. Jebsen TREC, University of Tromsø, Norway;††Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway;‡‡Department of Clinical Science, University of Bergen, Bergen, Norway;§§Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway;‖‖Research Institute of Internal Medicine, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital, Oslo, Norway; and¶¶Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Abstract
OBJECTIVE: To explore immune mechanisms and identify biomarkers associated with an inadequate immune recovery in patients with HIV with efficient antiretroviral therapy. DESIGN: A cross-sectional study of 67 HIV-infected patients on antiretroviral therapy for ≥24 months with HIV RNA ≤20 copies per milliliter; 41 were defined as immunological nonresponders (INR) (CD4 < 400 cells per microliter) and 26 as immunological responders (CD4 > 600 cells per microliter). CD4 counts were also registered 2 years after inclusion. METHODS: Cytokines, soluble markers of microbial translocation, and tryptophan catabolites were measured in plasma by multiplex assay, ELISA, or mass spectrometry. T-cell activation, differentiation, and regulatory T cells (Tregs) were analyzed by flow cytometry in 2 subgroups with comparable nadir CD4 counts. RESULTS: Plasma interferon-inducible protein-10 (IP-10) levels were higher (P < 0.05), the T cells were more activated (CD38HLA-DR) (P < 0.05), the naive/effector memory T-cell ratio was lower (P < 0.01) and the proportion of resting Tregs (CD4CD45RAFoxP3) was reduced (P < 0.001) in INR patients compared with immunological responders. INR patients with CD4 counts ≤300 cells per microliter also demonstrated a higher fraction of activated Tregs (aTreg) (CD4CD147CD25) (P < 0.05). In the INR group, the aTreg percentages correlated with plasma IP-10 levels and inversely with CD4 counts (both P < 0.01). IP-10 levels (P < 0.05) and kynurenine/tryptophan ratio (P < 0.01) were negatively associated with the CD4 count 2 years after inclusion. CONCLUSION: Patients with HIV with inadequate CD4 responses had higher levels of IP-10, more activated and differentiated T-cell phenotypes, as well as aTreg, compared with patients with satisfactory CD4 gain. High IP-10 levels were also associated with lower CD4 counts after 2 years.
OBJECTIVE: To explore immune mechanisms and identify biomarkers associated with an inadequate immune recovery in patients with HIV with efficient antiretroviral therapy. DESIGN: A cross-sectional study of 67 HIV-infectedpatients on antiretroviral therapy for ≥24 months with HIV RNA ≤20 copies per milliliter; 41 were defined as immunological nonresponders (INR) (CD4 < 400 cells per microliter) and 26 as immunological responders (CD4 > 600 cells per microliter). CD4 counts were also registered 2 years after inclusion. METHODS: Cytokines, soluble markers of microbial translocation, and tryptophan catabolites were measured in plasma by multiplex assay, ELISA, or mass spectrometry. T-cell activation, differentiation, and regulatory T cells (Tregs) were analyzed by flow cytometry in 2 subgroups with comparable nadir CD4 counts. RESULTS: Plasma interferon-inducible protein-10 (IP-10) levels were higher (P < 0.05), the T cells were more activated (CD38HLA-DR) (P < 0.05), the naive/effector memory T-cell ratio was lower (P < 0.01) and the proportion of resting Tregs (CD4CD45RAFoxP3) was reduced (P < 0.001) in INR patients compared with immunological responders. INR patients with CD4 counts ≤300 cells per microliter also demonstrated a higher fraction of activated Tregs (aTreg) (CD4CD147CD25) (P < 0.05). In the INR group, the aTreg percentages correlated with plasma IP-10 levels and inversely with CD4 counts (both P < 0.01). IP-10 levels (P < 0.05) and kynurenine/tryptophan ratio (P < 0.01) were negatively associated with the CD4 count 2 years after inclusion. CONCLUSION:Patients with HIV with inadequate CD4 responses had higher levels of IP-10, more activated and differentiated T-cell phenotypes, as well as aTreg, compared with patients with satisfactory CD4 gain. High IP-10 levels were also associated with lower CD4 counts after 2 years.
Authors: Eric G Meissner; Dongjun Chung; Betty Tsao; David W Haas; Netanya S Utay Journal: AIDS Res Hum Retroviruses Date: 2020-11-11 Impact factor: 1.723
Authors: Birgitte Stiksrud; Hans C D Aass; Kristina B Lorvik; Thor Ueland; Marius Trøseid; Anne M Dyrhol-Riise Journal: AIDS Date: 2019-06-01 Impact factor: 4.177
Authors: Malin Holm Meyer-Myklestad; Asle Wilhelm Medhus; Kristina Berg Lorvik; Ingebjørg Seljeflot; Simen Hyll Hansen; Kristian Holm; Birgitte Stiksrud; Marius Trøseid; Johannes Roksund Hov; Dag Kvale; Anne Margarita Dyrhol-Riise; Martin Kummen; Dag Henrik Reikvam Journal: J Infect Dis Date: 2022-02-15 Impact factor: 5.226
Authors: Gabriela Turk; Yanina Ghiglione; Macarena Hormanstorfer; Natalia Laufer; Romina Coloccini; Jimena Salido; César Trifone; María Julia Ruiz; Juliana Falivene; María Pía Holgado; María Paula Caruso; María Inés Figueroa; Horacio Salomón; Luis D Giavedoni; María de Los Ángeles Pando; María Magdalena Gherardi; Roberto Daniel Rabinovich; Pedro A Pury; Omar Sued Journal: Viruses Date: 2018-01-13 Impact factor: 5.048
Authors: Kristina Berg Lorvik; Malin Holm Meyer-Myklestad; Kushi Kushekar; Charlotte Handeland; Asle Wilhelm Medhus; Marius Lund-Iversen; Birgitte Stiksrud; Dag Kvale; Anne Margarita Dyrhol-Riise; Kjetil Taskén; Dag Henrik Reikvam Journal: Front Immunol Date: 2021-10-07 Impact factor: 7.561